Risk-Adapted Neoadjuvant Chemoradiotherapy in Rectal Cancer: Final Report of the OCUM Study. Ruppert R, Junginger T, Kube R, Strassburg J, et al. J Clin Oncol 2023;41:4025-4034.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Ruppert R, Junginger T, Kube R, Strassburg J, et al. Risk-Adapted Neoadjuvant Chemoradiotherapy in Rectal Cancer: Final Report of the OCUM Study. J Clin Oncol 2023;41:4025-4034.
PMID: 37335957